Latest from Apexian Pharmaceuticals

1. Apogee Therapeutics

   AbbVie · Jun 2026

   $10.9B

   Phase 2SCIL-13

2. Prometheus Biosciences

   Merck · Apr 2023

   $10.8B

   Phase 2IV/SCTL1A

3. Telavant

   Roche · Oct 2023

   $7.1B

   Phase 2SCTL1A

4. Arena Pharmaceuticals

   Pfizer · Dec 2021

   $6.7B

   Phase 3OralS1P

5. Nimbus TYK2 program

   Takeda · Dec 2022

   $6.0B

   Phase 2OralTYK2

6. Morphic

   Eli Lilly · Jul 2024

   $3.2B

   Phase 2Oralα4β7

Approximate announced deal values (upfront plus potential milestones), from company press releases and SEC filings. Development stage shown as at announcement of the acquisition. For industry context; illustrative only.